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Background. The Losartan Intervention For Endpoint reduc-
tion in hypertension (LIFE) study demonstrated the superiority
of a losartan-based regimen over atenolol-based regimen for re-
duction of cardiovascular (CV) morbidity and mortality. It has
been suggested that the LIFE study results may be related to
the effects of losartan on serum uric acid (SUA). SUA has been
proposed as an independent risk factor for CV morbidity and
death.
Methods. Cox regression analysis was used to assess relation-
ship of SUA and treatment regimens with the LIFE primary
composite outcome (CV death, fatal or nonfatal myocardial in-
farction, fatal or nonfatal stroke).
Results. Baseline SUA was significantly associated with
increased CV events [hazard ratio (HR) 1.024 (95% CI 1.017–
1.032) per 10 lmol/L, P < 0.0001] in the entire study popu-
lation. The association was significant in women [HR = 1.025
(1.013–1.037), P < 0.0001], but not in men [HR = 1.009 (0.998–
1.019), P = 0.108]. After adjustment for Framingham risk score
(FRS), SUA was no longer significant in the entire study pop-
ulation [HR = 1.006 (0.998–1.014), P = 0.122] or in men [HR
= 1.006 (0.995–1.017), P = 0.291], but was significant in women
[HR = 1.013 (1–1.025), P = 0.0457]. The baseline-to-end-of-
study increase in SUA (standard deviation, SD) was greater
(P < 0.0001) in atenolol-treated subjects (44.4 ± 72.5 lmol/L)
than in losartan-treated subjects (17.0 ± 69.8 lmol/L). SUA as
a time-varying covariate was strongly associated with events
(P < 0.0001) in the entire population. The contribution of SUA
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to the treatment effect of losartan on the primary composite
end point was 29% (14%-107%), P = 0.004. The association
between time-varying SUA and increased CV risk tended to be
stronger in women (P < 0.0001) than in men (P = 0.0658),
although the gender-outcome interaction was not significant
(P = 0.079).
Conclusion. The increase in SUA over 4.8 years in the LIFE
study was attenuated by losartan compared with atenolol treat-
ment, appearing to explain 29% of the treatment effect on the
primary composite end point. The association between SUA
and events was stronger in women than in men with or without
adjustment of FRS.
Several large epidemiologic studies have identified an
association between increased serum uric acid (SUA) and
cardiovascular risk in the general population [1–3], and
among patients with hypertension [4]. Although this as-
sociation has been known for over 50 years [5], interest in
the field has recently been renewed. Some studies have
claimed that SUA is an independent risk factor for cardio-
vascular disease (CVD) [6–7], whereas others have con-
cluded that there is merely an association of SUA with
other risk factors, including hypertension, renal disease,
elevated lipoprotein levels, and use of diuretic agents [8].
Some investigators have suggested a stronger indepen-
dent association of SUA with CVD in women than in
men [9–10], and in blacks than in whites [10–11]. The
association seems to be stronger in persons with hyper-
tension [4, 12–14] or congestive heart failure [15] than
in the general population. Several mechanisms by which
SUA could have a direct pathogenic role in CVD have
been suggested, but none have been confirmed in clini-
cal studies. Hyperuricemia has been linked to endothelial
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dysfunction [16–17] and impaired oxidative metabolism
[18], platelet adhesiveness [19], disturbed hemorheology
[20], and aggregation [21]. Uric acid is a marker of re-
nal injury [22–23] and may induce renal disease in rodent
models [24].
A feature of losartan that differentiates it from other
angiotensin II type 1 receptor antagonists is its lowering
of SUA [25] due to the ability of the losartan molecule
(not its active metabolite) to interfere with urate reab-
sorption in the renal proximal tubule [26]. In normal as
well as in hypertensive subjects, administration of losar-
tan produces sustained reduction in SUA levels [27].
Angiotensin-converting enzyme (ACE) inhibitors and
calcium-channel blockers also have modest uricosuric ef-
fects, but do not decrease SUA concentration [26]. Di-
uretics increase SUA levels, and b-blockers do not seem
to affect SUA concentration.
Most important, treatment-induced reduction of SUA
has never been shown to attenuate cardiovascular risk.
The Losartan Intervention For Endpoint reduction in
hypertension (LIFE) trial—which was designed to com-
pare the effects of losartan and atenolol treatment in a
high-risk, hypertensive population with left ventricular
hypertrophy—provides a unique opportunity not only to
elucidate the association of baseline SUA and other car-
diovascular risk factors with outcome in a high-risk pop-
ulation, but also to examine the association of change in
SUA level during losartan therapy with prognosis.
METHODS
Participants
The LIFE study design, organization, clinical measures,
end point definitions, basis for choice of comparative
agents, statistical power calculations, recruitment details,
baseline characteristics, 1-year follow-up, and primary re-
sults have been published [28–31]. Persons aged 55 to 80
years with previously treated or untreated hypertension
and electrocardiographic (ECG) signs of left ventricular
hypertrophy (LVH) were enrolled; 54% were women.
Those with secondary hypertension, myocardial infarc-
tion, or stroke within the previous 6 months; angina pec-
toris requiring treatment with b-blockers or calcium an-
tagonists; heart failure or left ventricular ejection frac-
tion ≤40%; or a disorder that, according to the treating
physician’s opinion, required treatment with study med-
ication or related drugs, were excluded. Eligible persons
were randomly assigned to losartan- or atenolol-based
regimens after 1 or 2 weeks of placebo if trough-sitting
blood pressures were 160–200 mm Hg systolic, 95–
115 mm Hg diastolic, or both. The trial protocol was
approved by local ethics committees and performed in ac-
cordance with the Declaration of Helsinki. The study was
overseen by an independent data and safety monitoring
board. All participants gave written informed consent.
Procedures
Study procedures were recently described [31]. Partic-
ipants were followed for a mean of 4.8 years with regular
visits and increases in drug doses to reach a target blood
pressure of less than 140/90 mm Hg. All screening, base-
line, serial, annual, and end point ECGs were centrally
assessed for signs of LVH, and were Minnesota coded at
one reading center. The ECG core center also assessed
silent and unrecognized myocardial infarctions. Because
combined ECG assessment of QRS voltage and dura-
tion enhances the detection of LVH at acceptable levels
of specificity, the product of QRS duration and Cornell
voltage was used as the primary measure to recognize
LVH.
Two central laboratories measured serum and plasma
concentrations of hemoglobin, creatinine, alanine amino-
transferase, glucose, uric acid, sodium, potassium, to-
tal and high-density lipoprotein (HDL) cholesterol, and
urine concentrations of albumin and creatinine. SUA was
measured by an enzymatic uricase method performed
on a Hitachi 747–200 analyzer (Roche Diagnostics, In-
dianapolis, IN, USA) (United States laboratory), and
PAP uricase method performed on a DAX96 analyzer
(Roche Diagnostics) (European laboratory). Urine al-
bumin concentration was determined by standard meth-
ods [32] by using a turbid metric method (Hitachi 717
analyzer, Boehringer Mannheim, Mannheim, Germany)
[33] on a single urine specimen. Both serum and urine
creatinine were analyzed using the Jaffe´ reaction with-
out deproteinizing and then quantified by a photometric
method by using the same analyzer. The urine albumin
concentration (mg/L) was expressed as a ratio to urinary
creatinine concentration (mmol/L), the urinary albumin:
creatinine ratio (UACR), to provide a composite mea-
sure (mg/mmol) of renal glomerular capillary permeabil-
ity adjusting for urine dilution [34]. In order to derive
United States measures of UACR (mg/g), urine creati-
nine (mg/dL) is multiplied by 8.84. New-onset diabetes
was assessed by the investigators according to the 1985
World Health Organization (WHO) criteria [35].
Follow-up of end points was stopped on September 16,
2001, when a sufficient number of primary end points for
study power were predicted to have occurred. Partici-
pants then had a follow-up clinic visit or at least a vital
status check within 6 weeks. All clinical data were verified
from source documents before entry into a laptop-based,
remote data-entry system by field monitors and electronic
transfer to a central database.
Statistical methods
Analyses of cardiovascular end points were based on
the intention-to-treat principle, consistent with all such
analyses used in the LIFE trial. Participants who expe-
rienced more than one end point event were counted as
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having had an event in all relevant end point analyses;
however, only the first event in a specific category was
counted in individual analyses.
The effect of baseline SUA on cardiovascular end
points was assessed by a Cox regression model. The con-
tribution of SUA to the losartan effect was assessed by
a Cox regression model with SUA included as a time-
varying covariate. The proportion of the losartan effect
explained by SUA was calculated by comparing the es-
timated losartan effect before and after the adjustment
for SUA [36]. Effects of other cardiovascular risk factors
were controlled for by using the baseline Framingham
risk score (FRS), which is based on gender, choles-
terol, high-density lipoprotein cholesterol, smoking sta-
tus, presence of diabetes and LVH, and systolic blood
pressure [37]. Compared with an alternative multiple re-
gression analysis entering the above variables separately,
the FRS was a more conservative adjustment (i.e., mini-
mized SUA effects), and, therefore, the preferred one.
Role of the funding source
All study data reside in the Merck & Co., Inc., database.
Merck provided the study steering committee with free
access to all data. The steering committee is free to inter-
pret data and write manuscripts.
RESULTS
Baseline variables
Mean baseline serum uric acid (United States male
370, female 325; Europe male 358, female 300 lmol/L),
hemoglobin, serum creatinine, cholesterol/HDL ratio,
serum glucose, urine albumin, and diastolic blood pres-
sure (DBP) were higher in men than in women. On the
other hand, women were older, had a higher body mass
index (BMI), higher total and HDL-cholesterol, systolic
blood pressure (SBP), and were more likely to have iso-
lated systolic hypertension (Table 1).
Serum creatinine, body weight, HDL-cholesterol,
hemoglobin, total cholesterol/HDL ratio, BMI, serum
glucose, DBP (but not SBP), and total cholesterol had
significant univariate correlations with SUA (all <0.0001)
(Table 2). Correlation coefficients for men and women
are shown separately in Table 2. In a stepwise, mul-
tiple regression analysis with SUA as the dependent
variable, serum creatinine, weight, hemoglobin, alcohol
consumption (continuous), total cholesterol/HDL ratio,
serum glucose, HDL-cholesterol, BMI, urine microal-
buminuria, smoking (continuous), and number of prior
antihypertensives were all independent explanatory vari-
ables (Table 3). Both BMI and weight remained selected,
indicating that height may be an important predictor as
well. Together, these variables explained 31% of the vari-
ation in SUA. Positive univariate relations of serum glu-
Table 1. Baseline demographic and clinical characteristics
All patients Women Men
Characteristic (N = 9193) (N = 4963) (N = 4230)
Age years 66.94 (7.0) 67.69 (6.99) 66.07 (6.92)
Weight kg 78.63 (14.94) 73.58 (14.30) 84.56 (13.43)
Body mass index kg/m2 27.99 (4.78) 28.31 (5.33) 27.62 (4.01)
Hemoglobin g/La 142.42 (12.06) 137.62 (10.15) 148.09 (11.68)
Serum creatinine 86.92 (20.20) 79.54 (17.53) 95.59 (19.68)
lmol/Lb
Serum uric acid 330.09 (78.19) 304.13 (71.90) 360.48 (74.21)
lmol/Lc
Total cholesterol 6.04 (1.12) 6.31 (1.11) 5.73 (1.06)
mmol/Ld
High density lipoprotein 1.49 (0.44) 1.62 (0.44) 1.34 (0.37)
cholesterol mmol/Ld
Cholesterol/high-density 4.34 (1.39) 4.15 (1.33) 4.56 (1.43)
lipoprotein ratio
Serum glucose 6.02 (2.18) 5.95 (2.16) 6.10 (2.21)
mmol/Le
Systolic blood pressure 174.43 (14.29) 175.34 (14.07) 173.36 (14.46)
mm Hg
Diastolic blood 97.79 (8.88) 97.12 (8.86) 98.58 (8.84)
pressure mm Hg
Isolated systolic 14.4 16.1 12.5
hypertension %
Urine albumin 63.8 (230.26) 49.06 (201.80) 81.06 (258.62)
mmol/Lf
Isolated systolic hypertension, systolic blood pressure 160–200 mm Hg and
diastolic blood pressure <90 mm Hg. Data are mean (standard deviation).
aTo convert values to grams per deciliter, multiply by 0.1.
bTo convert values to milligrams per deciliter, multiply by 0.0113.
cTo convert values to milligrams per deciliter, multiply by 0.0168.
dTo convert values to milligrams per deciliter, multiply by 38.67.
eTo convert values to milligrams per deciliter, multiply by 18.015.
fTo convert values to milligrams per deciliter, multiply by 0.1.
Table 2. Univariate correlations between baseline serum uric acid
and cardiovascular risk factors
Rho value
All patients Women Men
Variable (N = 9193) (N = 4963) (N = 4230)
Serum creatinine lmol/L 0.428b 0.352b 0.259b
Weight kg 0.343b 0.275b 0.188b
HDL-cholesterol mmol/L −0.307b −0.270b −0.134b
Cholesterol/HDL ratio 0.258b 0.256b 0.169b
Hemoglobin g/L 0.258b 0.115b 0.105b
Body mass index kg/m2 0.214b 0.300b 0.206b
Serum glucose mmol/L 0.131b 0.162b 0.039a
Diastolic blood pressure 0.066b 0.010 (NS) 0.067b
mm Hg
Cholesterol mmol/L −0.060b 0.007 (NS) 0.084b
NS, not significant.
aP < 0.05.
bP < 0.0001.
cose and smoking with SUA became negative in the mul-
tiple regression analysis.
Baseline SUA was significantly associated with in-
creased rate of the composite outcome of CV death, fatal
or nonfatal myocardial infarction, fatal or nonfatal stroke
[hazard ratio (HR) 1.024 (1.017–1.032) per 10 lmol/L,
P < 0.0001] (Fig. 1). The SUA-by-gender interaction was
significant (P = 0.0491). In women, baseline SUA re-
mained significantly associated with increased risk [HR =
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Table 3. Results of multiple regression analyses with SUA as dependent variable
Regression Standard Model
Variable coefficient error F value R square P value
Serum creatinine lmol/L 1.323b 0.042 1525.97 0.170 <0.0001
Weight kg 0.738b 0.096 669.81 0.238 <0.0001
Hemoglobin g/100 mL 0.759b 0.068 219.81 0.260 <0.0001
Alcohol drinks/wk 12.430b 0.820 148.99 0.275 <0.0001
Cholesterol/HDL ratio 5.705b 0.790 190.70 0.292 <0.0001
Serum glucose mmol/L −3.292b 0.349 77.89 0.300 <0.0001
HDL-cholesterol mmol/L −13.678b 2.699 24.22 0.303 <0.0001
BMI kg/m2 1.272b 0.279 17.59 0.304 <0.0001
Urine albumin mg/L 0.011a 0.003 10.36 0.305 =0.0013
Smoking cigarettes/day −1.453a 0.651 4.94 0.3055 =0.0263
Prior antihypertensives N 1.817a 0.852 4.55 0.3060 =0.0329
BMI, body mass index; HDL, high-density lipoprotein.
aP < 0.05.
bP < 0.001.
All, baseline SUA
      P < 0.0001
Women, baseline SUA
      P < 0.0001
Men, baseline SUA
      P = 0.108
All, adjusted SUA
      P = 0.122
Women, adjusted SUA
      P = 0.0457
Men, adjusted SUA
      P = 0.291
0.99 1.00 1.01 1.02 1.03 1.04
Hazard ratio
for composite CV end point
Fig. 1. Serum uric acid and cardiovascular risk per 10 lmol/L. Haz-
ard ratios for composite cardiovascular outcome (stroke, myocardial
infarction, and cardiovascular deaths) in the Losartan Intervention For
Endpoint reduction in hypertension (LIFE) study related to baseline
serum uric acid levels. When adjusted for Framingham risk score, the
hazard ratios remained statistically significant only in women.
1.025 (1.013–1.037), P < 0.0001] (Fig. 1). In men, how-
ever, SUA was not significantly associated with in-
creased events [HR = 1.009 (0.998–1.019), P = 0.108]
(Fig. 1). After adjustment for FRS, SUA was no longer
significant [HR = 1.006 (0.998–1.014), P = 0.122] in
the whole population, and the SUA-by-gender inter-
action was not significant (P = 0.421); however, the
association between baseline SUA and increased cardio-
vascular events was stronger in women (P = 0.0457) than
in men (P = 0.291). In an alternative analysis including
gender, age, smoking status, status of diabetes, systolic
blood pressure, and ratio of cholesterol/HDL cholesterol
separately, baseline SUA was significantly associated with
CV events [HR = 1.015 (1.006–1.024), P = 0.0005]. The
gender interaction was not significant (P = 0.9068). The
SUA effect was significant in both women [HR 1.016
(1.003–1.029), P = 0.014] and men [HR = 1.013 (1.002–
1.024), P = 0.026]. After adjustment for serum creatinine,
which was not included in FRS, SUA was still related to
the primary composite outcome (P = 0.0032), and after
adjustment for albumin/creatinine ratio, SUA was still
related to the primary composite outcome (P < 0.0001).
On-treatment SUA and composite cardiovascular
end point
SUA as a time-varying covariate was significantly as-
sociated with increased risk in the whole population (P <
0.0001) (Fig. 2). Although the SUA-by-gender interaction
was not significant (P = 0.079), the association between
time-varying SUA and increased cardiovascular events
tended to be stronger in women (P < 0.0001) than in
men (P = 0.0658). After adjustment for FRS, SUA was no
longer significant in the whole population (P = 0.0913).
Although the SUA-by-gender interaction was not signif-
icant (P = 0.282), the association between time-varying
SUA and increased cardiovascular events still tended to
be stronger in women (P = 0.032) than in men (P = 0.419).
The risk difference between losartan and atenolol de-
creased from 15% to 11% after adjustment for SUA as
a time-varying covariate. The estimated contribution of
SUA to the losartan effect was 29% (14%, 107%), P =
0.004. For women, the risk difference between losartan
and atenolol decreased from 19% to 16% after adjust-
ment for SUA as a time-varying covariate. The estimated
contribution of SUA to the losartan effect was 20% (7%,
98%), P = 0.009. For men, the risk difference between
losartan and atenolol decreased from 11% to 9% after
adjustment of SUA as a time-varying covariate, and the
estimated contribution of SUA to the losartan effect was
18% (−127%, 177%), P = 0.097.
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All,  SUA
       P < 0.0001
Women,  SUA
       P < 0.0001
Men,  SUA
       P = 0.0658
All, adjusted SUA
       P = 0.0913
Women, adjusted SUA
       P = 0.0320
Men, adjusted SUA
       P = 0.4191
0.99 1.00 1.01 1.02 1.03 1.04
Hazard ratio
for composite CV end point
Fig. 2. Serum uric acid on treatment and cardiovascular risk per 10
lmol/L. Hazard ratios for composite cardiovascular outcome (stroke,
myocardial infarction, and cardiovascular deaths) in the Losartan Inter-
vention For Endpoint reduction in hypertension (LIFE) study related
to on-treatment serum uric acid levels.
SUA, serum creatinine, and hemoglobin
The baseline-to-end-of study increase in SUA was
greater in the atenolol group (44.4 ± 72.5 lmol/L) than
in the losartan group (17.0 ± 69.8 lmol/L), P < 0.0001
(Fig. 3). The difference was significant after 1 year, and
was maintained throughout the study. The difference was
similar in men and women (Fig. 3). The distributions of
the dose of blinded study treatment for patients at the
end of follow-up or at occurrence of the first primary end
point, if earlier, and the distribution of additional therapy
on top of blinded study drug or hydrochlorothiazide were
not substantially different in the two groups. The mean
final losartan dose was 79 mg, and the mean final atenolol
dose was 76 mg. Patients taking losartan were more likely
to continue therapy, and the likelihood of receiving hy-
drochlorothiazide was the same in both groups.
Serum creatinine increased from 87.4 lmol/L ± 20.3
to 96.9 lmol/L ± 25.8 in the losartan group, and from
86.5 lmol/L ± 20.1 to 96.1 lmol/L ± 24.3 in the atenolol
group from baseline to end of the study (P = 0.337)
(Table 4). There was a strong positive association between
serum creatinine and SUA at end of study (r = 0.469,
P < 0.0001).
Hemoglobin decreased during the study and the
decline was more pronounced in the losartan group
(142.4 g/L ± 12.3 to 138.2 g/L ± 13.3) than in the
atenolol group (142.5 g/L ± 11.6 to 141.0 g/L ± 13.6)
275
300
325
350
375
400
425
450
SU
A,
 µ
m
ol
/L
0 1 2 3 4 5 6
Time, years
Losartan
Atenolol
A
275
300
325
350
375
400
425
450
SU
A,
 µ
m
ol
/L
0 1 2 3 4 5 6
Time, years
Losartan
Atenolol
B
275
300
325
350
375
400
425
450
SU
A,
 µ
m
ol
/L
0 1 2 3 4 5 6
Time, years
Losartan
Atenolol
C
Fig. 3. Serum uric acid by treatment group and gender. The increase
in serum uric acid throughout the study was significantly attenuated
in the losartan compared to the atenolol-treated group. (A) Overall
population (P < 0.0001). (B) Men (P < 0.0001). (C) Women (P <
0.0001). Year 0 refers to baseline.
(between-group difference, P < 0.0001) (Fig. 4). The in-
treatment decreases were similar in men and women
(Fig. 4). There was a positive association between end-of-
study hemoglobin and SUA (r = 0.174, P < 0.0001; P =
0.001 for women, and P = 0.610 for men). Other variables
(e.g., serum glucose, cholesterol, and HDL-cholesterol)
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Table 4. Mean changes in selected laboratory values from baseline to end of study
Losartan (N = 4605) Atenolol (N = 4588)
Baseline Year 5 Change Baseline Year 5 Change
Sodium mmol/L 140.111 139.538 −0.573 140.036 139.797 −0.239
Potassium mmol/L 4.141 4.109 −0.032 4.143 4.025 −0.118
SGPT (ALAT) lkat/L 0.513 0.474 −0.039 0.511 0.480 −0.030
Glucose mmol/L 5.900 6.116 0.216 5.816 6.367 0.551
Total cholesterol mmol/L 6.096 5.748 −0.348 6.122 5.805 −0.317
HDL-cholesterol mmol/L 1.526 1.497 −0.030 1.516 1.417 −0.099
Serum creatinine lmol/L 85.430 96.462 11.2 83.968 94.718 10.9
HDL = high-density lipoprotein.
did not change substantially during treatment in either
group (Table 4).
DISCUSSION
In the LIFE study baseline SUA was significantly as-
sociated with increased occurrence of the composite end
point of CV death, stroke, or myocardial infarction, even
with adjustment for other cardiovascular risk factors in
women, whereas in men, SUA was not associated with
increased events in univariate analyses or adjusted for
baseline Framingham risk score, but did have a weak as-
sociation when established risk factors were considered
separately. In addition, losartan, an angiotensin II type-1
receptor antagonist with effects on SUA unique within its
drug class, significantly attenuated the increase in SUA
compared with atenolol, a b-receptor blocker, during
4.8 years of follow-up in hypertensive adults with LVH.
The contribution of SUA to the treatment effect of losar-
tan on the primary composite end point (cardiovascular
death, nonfatal and fatal myocardial infarction, nonfatal
and fatal stroke) was estimated to be 29% (14%, 107%),
P = 0.004. The contribution of SUA to the losartan effect
tended to be stronger in women than in men.
The results from the LIFE study differ from other hy-
pertension studies comparing treatment based on a drug
from one of the newer classes with treatment based on an
older drug (diuretic or b-blocker). To date, no other study
of the treatment of essential hypertension has shown
unequivocal reduction of cardiovascular morbidity and
mortality beyond the effects of diuretics or b-blockers
[38]. The unique uric acid–lowering effect of losartan may
contribute to this novel finding. The LIFE study is also
the first study to show that reducing SUA is associated
with beneficial effect on outcomes in the treatment of
hypertension.
The association between SUA and risk for cardiovas-
cular events is well established, but whether this rela-
tionship is causal or not remains disputed. SUA may
have a pathogenic role in cardiovascular disease, or may
merely be a marker of other cardiovascular risk factors.
Epidemiologic studies have been unable to answer this
question, and controlled intervention studies in humans
are lacking. Even though the LIFE study was not de-
signed to address this issue, it provided a unique oppor-
tunity to study the effects of a drug that reduces SUA
on cardiovascular outcomes in a high-risk hypertensive
population.
The serum level of uric acid (which is filtered, reab-
sorbed, and secreted in the renal proximal tubules) is
closely related to renal function and to hypertension.
Serum creatinine is an independent cardiovascular risk
factor [39, 40], and increased SUA values may reflect
a decreased glomerular filtration rate (GFR) and may
thereby be a marker of cardiovascular risk. SUA is also
positively correlated with urinary albumin excretion [23].
After adjustment for these measures of renal function,
SUA still predicted cardiovascular events in the LIFE
study, indicating a more subtle relationship with renal
mechanisms or one independent of renal function. Hy-
peruricemia in hypertension may be caused by decreased
renal urate clearance independent of global changes in
glomerular filtration, which may be mediated by an in-
crease in serum lactate [41] that inhibits secretion of
urate by the tubular anion-exchange transport system.
Another possibility is that reduced uric acid excretion
may be linked to increased proximal tubular reabsorb-
tion of sodium and water because reabsorbtion of urate,
sodium, and water is conducted by the same transport
system [42]. The novel concept that salt-dependent hy-
pertension could result from renal microvascular injury
with local ischemia could provide a pathogenic link for
hyperuricemia with hypertension [43]. Hyperuricemia in
humans is associated with renal vasoconstriction [23] and
is positively correlated with plasma renin activity in hy-
pertensive subjects [44], suggesting that SUA could have
adverse effects that are mediated by renin-angiotensin-
aldosterone system activation. Hyperuricemia may be a
marker of renal disease or microvascular injury, but there
is also evidence that hyperuricemia may lead to renal dis-
ease [45–46]. A novel mechanism has recently been sug-
gested in a rodent model by which uric acid can stimulate
the development of hypertension by stimulating renal af-
ferent arteriopathy and tubulointerstitial disease, leading
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Fig. 4. Hemoglobin level by treatment group and gender. Hemoglobin
decreased during the study and the decline was more pronounced in
the losartan group than in the atenolol group. The differences in delta
values were similar for men and women. (A) Overall population. (B)
Men. (C) Women. Year 0 refers to baseline.
to hypertension [47–48]. Renal lesions and hypertension
could be prevented/reversed by lowering uric acid levels
and by treatment with an angiotensin-converting enzyme
(ACE) inhibitor or arginine [46]. Whether uric acid has
similar nephrotoxic and hypertension-promoting effects
in humans deserves further investigation.
SUA has long been known to be associated with
hemoglobin levels [49], and hyperuricemia is common
in patients with polycythemia. The relationship may
be explained by increased red cell degradation in sub-
jects with increased red cell mass. Increased hematocrit,
and thereby, blood viscosity, may link SUA and car-
diovascular risk because impaired hemorheology is a
well-documented risk factor for cardiovascular diseases
[50–52], and hemoglobin is a predictor of events in the
LIFE study [53]. Hemoglobin decreased more in the
losartan-compared with the atenolol-treated group. The
present study suggests an antierythropoietic effect of
losartan even in non-transplanted individuals in accor-
dance with some [54–55], but not all [56], previous studies.
Another explanation for reduced hemoglobin concen-
tration may be blood volume expansion and increased
plasma volume secondary to blocked angiotensin II-
mediated vasoconstriction, rather than reduced erythro-
poiesis. The number of erythrocytes was not measured in
the present study.
If SUA level is an independent cardiovascular risk fac-
tor, one may speculate whether lower hemoglobin levels,
and thereby, reduced cell degradation, would be accom-
panied by lower SUA, and thereby, reduced cardiovas-
cular risk. Interestingly, there was a positive association
between end-of-study hemoglobin and SUA in women,
but not in men, which may partly explain the strong rela-
tionship between cardiovascular events and SUA in the
women.
In accordance with reports from the Chicago Heart As-
sociation Detection Project [9] and NHANES I [10], we
found an association between baseline SUA and cardio-
vascular events in women, but not in men. There was also
a significantly stronger association between time-varying
SUA and cardiovascular outcome in women than in men.
Even though the gender difference seems to be a consis-
tent finding, a plausible mechanism is lacking. A closer
relationship between SUA and other cardiovascular risk
factors in women than in men, as in the LIFE study pop-
ulation (Table 2), may be one explanation; the close re-
lationship with SUA and age in women may be another.
While SUA levels are similar in boys and girls during
childhood, a gender difference appears at adolescence,
with lower levels in women than in men. This is probably
because of an increased renal clearance of urate related
to estrogen in premenopausal women [57] and may also
be related to lower hemoglobin levels in premenopausal
women. After menopause, however, SUA increases in
women and nearly reaches the levels in men of the
same age. Women taking hormone replacement therapy
have been shown to have significantly lower SUA than
those who did not [58]. Wingrove et al [59] postu-
lated that complex metabolic alterations associated with
menopause, rather than age, were linked to the observed
increase in SUA.
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SUA increased in both treatment groups during the
study period with an average of 10 lmol/L annually in
the atenolol group and 6 lmol/L annually in the losar-
tan group. At the time of a primary end point or the
end of follow-up, 86% of patients in the losartan group
versus 85% of patients in the atenolol group received hy-
drochlorothiazide without gender differences. The mean
dose of hydrochlorothiazide was approximately 20 mg
in each treatment group. For those who initiated hy-
drochlorothiazide during the trial, the average difference
in SUA from start of the study to the next SUA mea-
surement was 26 lmol/L (41 atenolol group, 12 losartan
group). There were no meaningful results by separat-
ing those with an increase >59.5 lmol/L (1 mg/dL) and
<59.5 lmol/L (1 mg/dL) in the present study. In addition,
both groups experienced a reduction in renal function,
as shown by increased serum creatinine during the mean
4.8-year study period. The decrease in renal function was
similar in the two treatment groups and most likely re-
flected age-related reduction in glomerular filtration rate
rather than either study drug action or effects of addi-
tional drugs or hydrochlorothiazide, which did not differ
between the groups. The parallel changes in serum cre-
atinine in the treatment groups made an adjustment for
creatinine as a time-varying covariate less meaningful, as
did the lack of change in plasma glucose in either group
throughout the study. The possibility of an influence of
other drugs affecting uric acid concentration is unlikely;
however, this also was not controlled for in the study.
The uric acid owering effect of losartan is the most rea-
sonable explanation for the difference in SUA increase in
the two groups. As a renal vasodilator, however, losartan
may decrease renal vasoconstriction, thus facilitating in-
creased tubular urate filtration compared with atenolol.
Measurements of serum creatinine in the study cannot
be used to exclude an improvement in glomerular filtra-
tion because small changes in GFR are not necessarily
reflected as changes in serum creatinine.
Diuretics are frequently used as antihypertensive med-
ication either alone or in combination with other drugs.
The development of hyperuricemia and gout is a well-
known side effect of this treatment regimen. In the LIFE
study 373 patients had one or more gout attacks reported
as adverse experiences, evenly divided between the two
groups, with 185 in the atenolol group and 188 in the
losartan group. The combination of losartan with a di-
uretic may be able to prevent hyperuricemia in anti-
hypertensive treatment and makes losartan a desirable
drug in combination with hydrochlorothiazide. Hyper-
uricemia occurring as a complication of diuretic therapy
has been implicated as a risk factor for cardiovascular
disease events. In the Systolic Hypertension in the El-
derly Program (SHEP) trial, participants who developed
hyperuricemia on chlorthalidone therapy suffered CVD
events at a rate similar to that of placebo-treated parti-
cipants [60].
CONCLUSION
The results of the LIFE study clearly support an as-
sociation between SUA and cardiovascular events in hy-
pertensive women. Furthermore, the present data sug-
gest that attenuating the increase in SUA, whether this
increase is related to a reduction in GFR or the use of di-
uretics, reduces cardiovascular events in a high-risk pop-
ulation. The unique results of the LIFE study may be
due in part to the specific feature of reduction of SUA by
losartan.
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